Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14


COX2/mPGES1/PGE2 pathway regulates PD-L1 expression in tumor-associated macrophages and myeloid-derived suppressor cells.

Prima V, Kaliberova LN, Kaliberov S, Curiel DT, Kusmartsev S.

Proc Natl Acad Sci U S A. 2017 Jan 31;114(5):1117-1122. doi: 10.1073/pnas.1612920114. Epub 2017 Jan 17.


Functional Characterization of ATP-Binding Cassette Transporter A3 Mutations from Infants with Respiratory Distress Syndrome.

Wambach JA, Yang P, Wegner DJ, Heins HB, Kaliberova LN, Kaliberov SA, Curiel DT, White FV, Hamvas A, Hackett BP, Cole FS.

Am J Respir Cell Mol Biol. 2016 Nov;55(5):716-721.


Retargeted adenoviruses for radiation-guided gene delivery.

Kaliberov SA, Kaliberova LN, Yan H, Kapoor V, Hallahan DE.

Cancer Gene Ther. 2016 Sep;23(9):303-14. doi: 10.1038/cgt.2016.32. Epub 2016 Aug 5.


Retargeted oncolytic adenovirus displaying a single variable domain of camelid heavy-chain-only antibody in a fiber protein.

van Erp EA, Kaliberova LN, Kaliberov SA, Curiel DT.

Mol Ther Oncolytics. 2015 Feb 18;2:15001. doi: 10.1038/mto.2015.1. eCollection 2015.


Adenoviral targeting using genetically incorporated camelid single variable domains.

Kaliberov SA, Kaliberova LN, Buggio M, Tremblay JM, Shoemaker CB, Curiel DT.

Lab Invest. 2014 Aug;94(8):893-905. doi: 10.1038/labinvest.2014.82. Epub 2014 Jun 16.


Experimental virotherapy of chemoresistant pancreatic carcinoma using infectivity-enhanced fiber-mosaic oncolytic adenovirus.

Kaliberov SA, Kaliberova LN, Buchsbaum DJ, Curiel DT.

Cancer Gene Ther. 2014 Jul;21(7):264-74. doi: 10.1038/cgt.2014.26. Epub 2014 Jun 6.


Retargeting of gene expression using endothelium specific hexon modified adenoviral vector.

Kaliberov SA, Kaliberova LN, Hong Lu Z, Preuss MA, Barnes JA, Stockard CR, Grizzle WE, Arbeit JM, Curiel DT.

Virology. 2013 Dec;447(1-2):312-25. doi: 10.1016/j.virol.2013.09.020. Epub 2013 Oct 15.


Experimental cancer therapy using restoration of NAD+ -linked 15-hydroxyprostaglandin dehydrogenase expression.

Kaliberova LN, Kusmartsev SA, Krendelchtchikova V, Stockard CR, Grizzle WE, Buchsbaum DJ, Kaliberov SA.

Mol Cancer Ther. 2009 Nov;8(11):3130-9. doi: 10.1158/1535-7163.MCT-09-0270. Epub 2009 Nov 3.


CRAdRGDflt-IL24 virotherapy in combination with chemotherapy of experimental glioma.

Kaliberova LN, Krendelchtchikova V, Harmon DK, Stockard CR, Petersen AS, Markert JM, Gillespie GY, Grizzle WE, Buchsbaum DJ, Kaliberov SA.

Cancer Gene Ther. 2009 Oct;16(10):794-805. doi: 10.1038/cgt.2009.23. Epub 2009 Apr 10.


Molecular chemotherapy of pancreatic cancer using novel mutant bacterial cytosine deaminase gene.

Kaliberova LN, Della Manna DL, Krendelchtchikova V, Black ME, Buchsbaum DJ, Kaliberov SA.

Mol Cancer Ther. 2008 Sep;7(9):2845-54. doi: 10.1158/1535-7163.MCT-08-0347.


Mutation of Escherichia coli cytosine deaminase significantly enhances molecular chemotherapy of human glioma.

Kaliberov SA, Market JM, Gillespie GY, Krendelchtchikova V, Della Manna D, Sellers JC, Kaliberova LN, Black ME, Buchsbaum DJ.

Gene Ther. 2007 Jul;14(14):1111-9. Epub 2007 May 10.


Combination of cytosine deaminase suicide gene expression with DR5 antibody treatment increases cancer cell cytotoxicity.

Kaliberov SA, Chiz S, Kaliberova LN, Krendelchtchikova V, Della Manna D, Zhou T, Buchsbaum DJ.

Cancer Gene Ther. 2006 Feb;13(2):203-14.


Combined ionizing radiation and sKDR gene delivery for treatment of prostate carcinomas.

Kaliberov SA, Kaliberova LN, Buchsbaum DJ.

Gene Ther. 2005 Mar;12(5):407-17.


Adenovirus-mediated FLT1-targeted proapoptotic gene therapy of human prostate cancer.

Kaliberov SA, Kaliberova LN, Stockard CR, Grizzle WE, Buchsbaum DJ.

Mol Ther. 2004 Dec;10(6):1059-70.

Supplemental Content

Loading ...
Support Center